Biosimilars Market by Product (Recombinant Non-glycosylated Proteins (Insulin, rHGH, Interferon), glycosylated (mAb, EPO), Peptides (Glucagon, Calcitonin)), Manufacturing (In-House, CMO), Application (Oncology, Blood Disorders) - Global Forecast to 2021

 Published On: Jan, 2017 |    No of Pages: 154 |  Published By: MarketsandMarkets | Format: PDF
Request Free Sample
The global biosimilars market is expected to reach USD 10.90 billion by 2021 from USD 3.39 billion in 2016, at a CAGR of 26.3%. The biosimilars market is broadly classified into product, manufacturing type, application, and region.

On the basis of product, the biosimilars market is segmented into recombinant non-glycosylated proteins, recombinant glycosylated proteins, and recombinant peptides. The recombinant non-glycosylated proteins segment is estimated to account for the largest share of the biosimilars market, in 2016. Factors such as new product launches, cost-effectiveness, growing incidence of diabetes, and presence of many biosimilar versions of insulin in the pipeline are driving growth in this market.

On the basis of manufacturing type, the market is segmented into in-house manufacturing and contract manufacturing organizations. The contract manufacturing organizations segment is projected to witness the highest CAGR during the forecast period.

On the basis of application, the market is segmented into oncology, blood disorders, chronic and autoimmune diseases, growth hormone deficiency, infectious diseases, and other applications. In 2016, the oncology segment is expected to account for the largest share of the market.

Geographically, the biosimilars market is dominated by Europe, followed by Asia, North America, and the Rest of the World (RoW). Growth in the European market is attributed to the growing pressure to curtail healthcare costs, patent expiry of biologics & the arrival of new biosimilars, and the rising incidence of chronic disorders.

Apart from comprehensive geographic and product analysis and market sizing, the report also provides a competitive landscape that covers the growth strategies adopted by industry players over the last three years. In addition, the company profiles comprise the product portfolios, developments, and strategies adopted by the market players to maintain and increase their shares in the market. The above-mentioned market research data, current market size, and forecast of the future trends will help key market players and new entrants to make the necessary decisions regarding product offerings, geographic focus, change in strategic approach, and levels of output in order to remain successful in the market.

The key players in the biosimilars market include Pfizer Inc. (U.S.), Sandoz International GmbH (Germany), Teva Pharmaceuticals Industries Ltd. (Israel), Amgen Inc. (U.S.), Biocon Ltd. (India), Dr. Reddy’s Laboratories Ltd. (India), F. Hoffmann-La Roche Ltd. (Switzerland), Celltrion Inc. (South Korea), and Samsung Bioepis (South Korea).

Reasons to Buy the Report:

This report will enable both established firms as well as new entrants/smaller firms to gauge the pulse of the market, which in turn will help these firms garner greater market shares. Firms purchasing the report can use any one or a combination of the below-mentioned five strategies (market penetration, product development/innovation, market development, market diversification, and competitive assessment) for strengthening their market shares.

The report provides insights on the following pointers:

• Market Penetration: Comprehensive information on the product portfolios of the top players in the biosimilars market. The report analyses the biosimilars market by product, manufacturing type, and application.
• Product Development/Innovation: Detailed insights on the upcoming technologies, R&D activities, and new product launches in the biosimilars market
• Competitive Assessment: In-depth assessment of the market strategies, geographic and business segments, and product portfolios of the leading players in the biosimilars market
• Market Development: Comprehensive information about emerging markets. This report analyzes the market for various biosimilars products across geographies
• Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the biosimilars market
TABLE OF CONTENTS

1 INTRODUCTION 15
1.1 OBJECTIVES OF THE STUDY 15
1.2 MARKET DEFINITION 15
1.3 MARKET SCOPE 16
1.3.1 MARKET COVERED 16
1.3.2 YEARS CONSIDERED FOR THE STUDY 17
1.4 CURRENCY 17
1.5 LIMITATIONS 17
1.6 STAKEHOLDERS 17

2 RESEARCH METHODOLOGY 18
2.1 SECONDARY DATA 19
2.1.1 KEY DATA FROM SECONDARY SOURCES 19
2.2 PRIMARY DATA 20
2.2.1 KEY DATA FROM PRIMARY SOURCES 21
2.3 MARKET SIZE ESTIMATION 22
2.3.1 BOTTOM-UP APPROACH 22
2.3.2 TOP-DOWN APPROACH 23
2.4 MARKET BREAKDOWN & DATA TRIANGULATION 24
2.5 ASSUMPTIONS FOR THE STUDY 25

3 EXECUTIVE SUMMARY 26
3.1 INTRODUCTION 26
3.2 CONCLUSION 29

4 PREMIUM INSIGHTS 30
4.1 BIOSIMILARS: MARKET OVERVIEW 30
4.2 GEOGRAPHIC ANALYSIS: BIOSIMILARS MARKET, BY PRODUCT 31
4.3 BIOSIMILARS MARKET SIZE, BY APPLICATION, 2016 VS. 2021 32

5 MARKET OVERVIEW 33
5.1 INTRODUCTION 34
5.2 MARKET DYNAMICS 34
5.2.1 DRIVERS 35
5.2.1.1 Rising incidences of diseases 35
5.2.1.2 Increasing demand for biosimilar drugs due to their cost-effectiveness 36
5.2.1.3 Growing pressure to curtail healthcare expenditure 36
5.2.1.4 Rising geriatric population 37
5.2.1.5 Strategic collaborations resulting in enhanced productivity and clinical trial activities for biosimilars 38
5.2.1.6 Increasing government support and initiatives to develop and promote biosimilars 39
5.2.2 RESTRAINTS 39
5.2.2.1 Complexities in manufacturing and high costs 39
5.2.2.2 Innovative strategies by biologic drug manufacturers 40
5.2.3 OPPORTUNITIES 40
5.2.3.1 Emerging markets 40
5.2.3.2 New indications and patent expiry of biologic products 40
5.2.4 CHALLENGE 42
5.2.4.1 Stringent regulatory requirements to adversely affect investments in biosimilars 42
5.3 KEY PIPELINE PRODUCTS 42
5.4 REGULATORY OUTLOOK 44
5.4.1 NORTH AMERICA 44
5.4.1.1 U.S. 44
5.4.1.2 Canada 44
5.4.2 EUROPE 44
5.4.3 ASIA 45
5.4.3.1 China 45
5.4.3.2 India 46
5.4.3.3 Japan 46
5.4.3.4 South Korea 46
5.4.4 REST OF THE WORLD 46
5.4.4.1 Brazil 46
5.4.4.2 Mexico 46
5.4.4.3 Argentina 47
5.4.4.4 Saudi Arabia 47
5.5 BIOSIMILARS SERVICES INDUSTRY INSIGHTS 47
5.5.1 INTRODUCTION 47
5.5.2 CONTRACT MANUFACTURING ORGANIZATIONS 48
5.5.3 CONTRACT RESEARCH ORGANIZATIONS 48
5.5.4 OTHER SERVICES (NONCLINICAL & BIOINFORMATICS) 49

6 BIOSIMILARS MARKET, BY TYPE OF PRODUCT 50
6.1 INTRODUCTION 51
6.2 RECOMBINANT NON-GLYCOSYLATED PROTEINS 52
6.2.1 INSULIN 54
6.2.2 RECOMBINANT HUMAN GROWTH HORMONE (RHGH) 55
6.2.3 GRANULOCYTE COLONY-STIMULATING FACTOR (FILGRASTIM) 56
6.2.4 INTERFERONS 58
6.3 RECOMBINANT GLYCOSYLATED PROTEINS 59
6.3.1 ERYTHROPOIETIN (EPO) 61
6.3.2 MONOCLONAL ANTIBODIES (MABS) 62
6.3.3 FOLLITROPIN 63
6.4 RECOMBINANT PEPTIDES 64
6.4.1 GLUCAGON 66
6.4.2 CALCITONIN 66

7 BIOSIMILARS MARKET, BY TYPE OF MANUFACTURING 68
7.1 INTRODUCTION 69
7.2 IN-HOUSE MANUFACTURING 70
7.3 CONTRACT MANUFACTURING ORGANIZATIONS 71

8 BIOSIMILARS MARKET, BY APPLICATION 72
8.1 INTRODUCTION 73
8.2 ONCOLOGY 74
8.3 CHRONIC AND AUTOIMMUNE DISEASES 76
8.4 BLOOD DISORDERS 77
8.5 GROWTH HORMONE DEFICIENCY 78
8.6 INFECTIOUS DISEASES 79
8.7 OTHER APPLICATIONS 80

9 BIOSIMILARS MARKET, BY REGION 81
9.1 INTRODUCTION 82
9.2 NORTH AMERICA 83
9.2.1 U.S. 88
9.2.2 CANADA 89
9.3 EUROPE 90
9.3.1 GERMANY 95
9.3.2 FRANCE 95
9.3.3 U.K. 96
9.3.4 ITALY 97
9.3.5 SPAIN 97
9.3.6 REST OF EUROPE 98
9.4 ASIA 99
9.4.1 CHINA 104
9.4.2 INDIA 105
9.4.3 JAPAN 106
9.4.4 SOUTH KOREA 107
9.4.5 REST OF ASIA (ROA) 108
9.5 REST OF THE WORLD (ROW) 109

10 COMPETITIVE LANDSCAPE 113
10.1 OVERVIEW 113
10.2 MARKET SHARE ANALYSIS 114
10.3 COMPETITIVE SITUATION AND TRENDS 115
10.3.1 REGULATORY APPROVALS 116
10.3.2 AGREEMENTS, COLLABORATIONS, AND PARTNERSHIPS 116
10.3.3 PRODUCT LAUNCHES 117
10.3.4 ACQUISITIONS 118
10.3.5 EXPANSIONS 118
10.3.6 OTHER DEVELOPMENTS 119

11 COMPANY PROFILES 120 (Introduction, Products & Services, Strategy, & Analyst Insights, Developments, MnM View)*
11.1 INTRODUCTION 120
11.2 PFIZER INC. 121
11.3 SANDOZ INTERNATIONAL GMBH (A DIVISION OF NOVARTIS INTERNATIONAL AG) 123
11.4 TEVA PHARMACEUTICAL INDUSTRIES LTD. 126
11.5 F. HOFFMANN-LA ROCHE LTD. 128
11.6 AMGEN INC. 130
11.7 BIOCON LTD. 132
11.8 DR. REDDY'S LABORATORIES 134
11.9 CELLTRION INC. 136
11.10 MYLAN INC. 138
11.11 SAMSUNG BIOEPIS 140

*Details on MarketsandMarkets view, Introduction, Product & Services, Strategy, & Analyst Insights, New Developments might not be captured in case of unlisted companies.

12 APPENDIX 142
12.1 INSIGHTS OF INDUSTRY EXPERTS 142
12.2 DISCUSSION GUIDE 143
12.3 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 147
12.4 INTRODUCING RT: REAL-TIME MARKET INTELLIGENCE 149
12.5 AVAILABLE CUSTOMIZATIONS 150
12.6 RELATED REPORTS 151
12.7 AUTHOR DETAILS 152

LIST OF TABLES

TABLE 1 BIOSIMILARS MARKET SUMMARY 26
TABLE 2 BIOSIMILARS MARKET: MAJOR COLLABORATIONS (2012–2015) 38
TABLE 3 LIST OF KEY BIOLOGICS UNDER THE THREAT OF PATENT EXPIRY 41
TABLE 4 BIOSIMILARS IN CLINICAL TRIALS 42
TABLE 5 STATUS OF REGULATORY PATHWAY IN NORTH AMERICA 44
TABLE 6 SUBSTITUTION STATUS IN EUROPEAN COUNTRIES 45
TABLE 7 STATUS OF REGULATORY PATHWAY IN ASIA 46
TABLE 8 STATUS OF REGULATORY PATHWAY IN THE ROW 47
TABLE 9 JOINT VENTURES BETWEEN CMOS & PHARMACEUTICAL COMPANIES FOR BIOSIMILARS 48
TABLE 10 BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2014–2021 (USD MILLION) 51
TABLE 11 BIOSIMILAR RECOMBINANT NON-GLYCOSYLATED PROTEINS MARKET SIZE, BY TYPE, 2014–2021 (USD MILLION) 52
TABLE 12 BIOSIMILAR RECOMBINANT NON-GLYCOSYLATED PROTEINS MARKET SIZE, BY REGION, 2014–2021 (USD MILLION) 53
TABLE 13 NORTH AMERICA: BIOSIMILAR RECOMBINANT NON-GLYCOSYLATED PROTEINS MARKET SIZE, BY COUNTRY, 2014–2021 (USD MILLION) 53
TABLE 14 EUROPE: BIOSIMILAR RECOMBINANT NON-GLYCOSYLATED PROTEINS MARKET SIZE, BY COUNTRY, 2014–2021 (USD MILLION) 53
TABLE 15 ASIA: BIOSIMILAR RECOMBINANT NON-GLYCOSYLATED PROTEINS MARKET SIZE, BY COUNTRY, 2014–2021 (USD MILLION) 54
TABLE 16 BIOSIMILAR INSULIN MARKET SIZE, BY REGION, 2014 –2021 (USD MILLION) 55
TABLE 17 BIOSIMILAR RECOMBINANT HUMAN GROWTH HORMONE MARKET SIZE, BY REGION, 2014–2021 (USD MILLION) 56
TABLE 18 LIST OF APPROVED BIOSIMILARS FOR GRANULOCYTE COLONY-STIMULATING FACTOR PRODUCTS FROM 2013 TO 2016 57
TABLE 19 BIOSIMILAR GRANULOCYTE COLONY-STIMULATING FACTOR MARKET SIZE, BY REGION, 2014–2021 (USD MILLION) 57
TABLE 20 BIOSIMILAR INTERFERONS MARKET SIZE, BY REGION, 2014–2021 (USD MILLION) 58
TABLE 21 BIOSIMILAR RECOMBINANT GLYCOSYLATED PROTEINS MARKET SIZE, BY TYPE, 2014–2021 (USD MILLION) 59
TABLE 22 BIOSIMILAR RECOMBINANT GLYCOSYLATED PROTEINS MARKET SIZE, BY REGION, 2014–2021 (USD MILLION) 60
TABLE 23 NORTH AMERICA: BIOSIMILAR RECOMBINANT GLYCOSYLATED PROTEINS MARKET SIZE, BY COUNTRY, 2014–2021 (USD MILLION) 60
TABLE 24 EUROPE: BIOSIMILAR RECOMBINANT GLYCOSYLATED PROTEINS MARKET SIZE, BY COUNTRY, 2014–2021 (USD MILLION) 60
TABLE 25 ASIA: BIOSIMILAR RECOMBINANT GLYCOSYLATED PROTEINS MARKET SIZE, BY COUNTRY, 2014–2021 (USD MILLION) 61
TABLE 26 BIOSIMILAR ERYTHROPOIETIN MARKET SIZE, BY REGION, 2014–2021 (USD MILLION) 62
TABLE 27 BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY REGION, 2014–2021 (USD MILLION) 63
TABLE 28 BIOSIMILAR FOLLITROPIN MARKET SIZE, BY REGION, 2014–2021 (USD MILLION) 63
TABLE 29 BIOSIMILAR RECOMBINANT PEPTIDES MARKET SIZE, BY TYPE, 2014–2021 (USD MILLION) 64
TABLE 30 BIOSIMILAR RECOMBINANT PEPTIDES MARKET SIZE, BY REGION, 2014–2021 (USD MILLION) 64
TABLE 31 NORTH AMERICA: BIOSIMILAR RECOMBINANT PEPTIDES MARKET SIZE, BY COUNTRY, 2014–2021 (USD MILLION) 65
TABLE 32 EUROPE: BIOSIMILAR RECOMBINANT PEPTIDES MARKET SIZE, BY COUNTRY, 2014–2021 (USD MILLION) 65
TABLE 33 ASIA: BIOSIMILAR RECOMBINANT PEPTIDES MARKET SIZE, BY COUNTRY, 2014–2021 (USD MILLION) 65
TABLE 34 BIOSIMILAR GLUCAGON MARKET SIZE, BY REGION, 2014–2021 (USD MILLION) 66
TABLE 35 BIOSIMILAR CALCITONIN MARKET SIZE, BY REGION, 2014–2021 (USD MILLION) 67
TABLE 36 BIOSIMILARS MARKET SIZE, BY MANUFACTURING TYPE, 2014–2021 (USD MILLION) 69
TABLE 37 BIOSIMILARS MARKET SIZE FOR IN-HOUSE MANUFACTUIRNG, BY REGION, 2014–2021 (USD MILLION) 70
TABLE 38 BIOSIMILARS MARKET SIZE FOR CONTRACT MANUFACTURING ORGANIZATIONS, BY REGION, 2014–2021 (USD MILLION) 71
TABLE 39 BIOSIMILARS MARKET SIZE, BY APPLICATION, 2014–2021 (USD MILLION) 74
TABLE 40 BIOSIMILARS MARKET SIZE FOR ONCOLOGY, BY REGION, 2014–2021 (USD MILLION) 75
TABLE 41 BIOSIMILARS MARKET SIZE FOR CHRONIC AND AUTOIMMUNE DISEASES, BY REGION, 2014–2021 (USD MILLION) 76
TABLE 42 BIOSIMILARS MARKET SIZE FOR BLOOD DISORDERS, BY REGION, 2014–2021 (USD MILLION) 77
TABLE 43 BIOSIMILARS MARKET SIZE FOR GROWTH HORMONE DEFICIENCY, BY REGION, 2014–2021 (USD MILLION) 78
TABLE 44 BIOSIMILARS MARKET SIZE FOR INFECTIOUS DISEASES, BY REGION, 2014–2021 (USD MILLION) 79
TABLE 45 BIOSIMILARS MARKET SIZE FOR OTHER APPLICATIONS, BY REGION, 2014–2021 (USD MILLION) 80
TABLE 46 BIOSIMILARS MARKET SIZE, BY REGION, 2014–2021 (USD MILLION) 82
TABLE 47 NORTH AMERICA: BIOSIMILARS MARKET SIZE, BY COUNTRY, 2014–2021 (USD MILLION) 83
TABLE 48 NORTH AMERICA: BIOSIMILARS MARKET SIZE, BY PRODUCT, 2014–2021 (USD MILLION) 85
TABLE 49 NORTH AMERICA: RECOMBINANT NON-GLYCOSYLATED PROTEINS MARKET SIZE, BY TYPE, 2014–2021 (USD MILLION) 85
TABLE 50 NORTH AMERICA: RECOMBINANT GLYCOSYLATED PROTEINS MARKET SIZE, BY TYPE, 2014–2021 (USD MILLION) 85
TABLE 51 NORTH AMERICA: RECOMBINANT PEPTIDES MARKET SIZE, BY TYPE, 2014–2021 (USD MILLION) 86
TABLE 52 NORTH AMERICA: BIOSIMILARS MARKET SIZE, BY APPLICATION, 2014–2021 (USD MILLION) 87
TABLE 53 NORTH AMERICA: BIOSIMILARS MARKET SIZE, BY MANUFACTURING TYPE, 2014–2021 (USD MILLION) 87
TABLE 54 U.S.: BIOSIMILARS MARKET SIZE, BY PRODUCT, 2014–2021 (USD MILLION) 88
TABLE 55 CANADA: BIOSIMILARS MARKET SIZE, BY PRODUCT, 2014–2021 (USD MILLION) 89
TABLE 56 EUROPE: BIOSIMILARS MARKET SIZE, BY COUNTRY, 2014–2021 (USD MILLION) 92
TABLE 57 EUROPE: BIOSIMILARS MARKET SIZE, BY PRODUCT, 2014–2021 (USD MILLION) 92
TABLE 58 EUROPE: RECOMBINANT NON-GLYCOSYLATED PROTEINS MARKET SIZE, BY TYPE, 2014–2021 (USD MILLION) 92
TABLE 59 EUROPE: RECOMBINANT GLYCOSYLATED PROTEINS MARKET SIZE, BY TYPE, 2014–2021 (USD MILLION) 93
TABLE 60 EUROPE: RECOMBINANT PEPTIDES MARKET SIZE, BY TYPE, 2014–2021 (USD MILLION) 93
TABLE 61 EUROPE: BIOSIMILARS MARKET SIZE, BY APPLICATION, 2014–2021 (USD MILLION) 94
TABLE 62 EUROPE: BIOSIMILARS MARKET SIZE, BY MANUFACTURING TYPE, 2014–2021 (USD MILLION) 94
TABLE 63 GERMANY: BIOSIMILARS MARKET SIZE, BY PRODUCT, 2014–2021 (USD MILLION) 95
TABLE 64 FRANCE: BIOSIMILARS MARKET SIZE, BY PRODUCT, 2014–2021 (USD MILLION) 96
TABLE 65 U.K.: BIOSIMILARS MARKET SIZE, BY PRODUCT, 2014–2021 (USD MILLION) 96
TABLE 66 ITALY: BIOSIMILARS MARKET SIZE, BY PRODUCT, 2014–2021 (USD MILLION) 97
TABLE 67 SPAIN: BIOSIMILARS MARKET SIZE, BY PRODUCT, 2014–2021 (USD MILLION) 98
TABLE 68 ROE: BIOSIMILARS MARKET SIZE, BY PRODUCT, 2014–2021 (USD MILLION) 98
TABLE 69 ASIA: BIOSIMILARS MARKET SIZE, BY COUNTRY, 2014–2021 (USD MILLION) 101
TABLE 70 ASIA: BIOSIMILARS MARKET SIZE, BY PRODUCT, 2014–2021 (USD MILLION) 101
TABLE 71 ASIA: RECOMBINANT NON-GLYCOSYLATED PROTEINS MARKET SIZE, BY TYPE, 2014–2021 (USD MILLION) 102
TABLE 72 ASIA: RECOMBINANT GLYCOSYLATED PROTEINS MARKET SIZE, BY TYPE, 2014–2021 (USD MILLION) 102
TABLE 73 ASIA: RECOMBINANT PEPTIDES MARKET SIZE, BY TYPE, 2014–2021 (USD MILLION) 102
TABLE 74 ASIA: BIOSIMILARS MARKET SIZE, BY APPLICATION, 2014–2021 (USD MILLION) 103
TABLE 75 ASIA: BIOSIMILARS MARKET SIZE, BY MANUFACTURING TYPE, 2014–2021 (USD MILLION) 104
TABLE 76 CHINA: BIOSIMILARS MARKET SIZE, BY PRODUCT, 2014–2021 (USD MILLION) 104
TABLE 77 INDIA: BIOSIMILARS MARKET SIZE, BY PRODUCT, 2014–2021 (USD MILLION) 105
TABLE 78 JAPAN: BIOSIMILARS MARKET SIZE, BY PRODUCT, 2014–2021 (USD MILLION) 106
TABLE 79 SOUTH KOREA: BIOSIMILARS MARKET SIZE, BY PRODUCT, 2014–2021 (USD MILLION) 107
TABLE 80 ROA: BIOSIMILARS MARKET SIZE, BY PRODUCT, 2014–2021 (USD MILLION) 108
TABLE 81 ROW: BIOSIMILARS MARKET SIZE, BY PRODUCT, 2014–2021 (USD MILLION) 111
TABLE 82 ROW: RECOMBINANT NON-GLYCOSYLATED PROTEINS MARKET SIZE, BY TYPE, 2014–2021 (USD MILLION) 111
TABLE 83 ROW: RECOMBINANT GLYCOSYLATED PROTEINS MARKET SIZE, BY TYPE, 2014–2021 (USD MILLION) 112
TABLE 84 ROW: RECOMBINANT PEPTIDES MARKET SIZE, BY TYPE, 2014–2021 (USD MILLION) 112
TABLE 85 ROW: BIOSIMILARS MARKET SIZE, BY APPLICATION, 2014–2021 (USD MILLION) 112
TABLE 86 REGULATORY APPROVALS, 2013–2016 116
TABLE 87 AGREEMENTS, COLLABORATIONS, AND PARTNERSHIPS, 2013–2016 116
TABLE 88 PRODUCT LAUNCHES, 2013–2016 117
TABLE 89 ACQUISITIONS, 2013–2016 118
TABLE 90 EXPANSIONS, 2013–2016 118
TABLE 91 OTHER DEVELOPMENTS 119

LIST OF FIGURES

FIGURE 1 RESEARCH METHODOLOGY 18
FIGURE 2 BIOSIMILARS MARKET: BOTTOM-UP APPROACH 22
FIGURE 3 TOP-DOWN APPROACH 23
FIGURE 4 DATA TRIANGULATION METHODOLOGY 24
FIGURE 5 BIOSIMILARS MARKET SIZE, BY PRODUCT, 2016 VS. 2021 (USD BILLION) 27
FIGURE 6 BIOSIMILARS MARKET SIZE, BY TYPE OF MANUFACTURING, 2016 VS. 2021 (USD BILLION) 27
FIGURE 7 BIOSIMILARS MARKET SIZE, BY APPLICATION, 2016 VS. 2021 (USD BILLION) 28
FIGURE 8 GEOGRAPHICAL SNAPSHOT OF THE BIOSIMILARS MARKET 28
FIGURE 9 BIOSIMILARS MARKET TO REGISTER A HIGH, DOUBLE-DIGIT GROWTH RATE DURING THE FORECAST PERIOD 30
FIGURE 10 RECOMBINANT NON-GLYCOSYLATED PROTEINS SEGMENT TO ACCOUNT FOR THE LARGEST MARKET SHARE IN 2016 31
FIGURE 11 ONCOLOGY SEGMENT WILL CONTINUE TO DOMINATE THE BIOSIMILARS MARKET IN 2021 32
FIGURE 12 ASIA TO REGISTER THE HIGHEST CAGR DURING THE FORECAST PERIOD 32
FIGURE 13 BIOSIMILARS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, & CHALLENGES 34
FIGURE 14 GLOBAL INCIDENCES OF TOP TEN CANCER 35
FIGURE 15 GLOBAL INCIDENCES OF DIABETIES 36
FIGURE 16 BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2014–2021 51
FIGURE 17 IN-HOUSE MANUFACTURING SEGMENT TO DOMINATE THE BIOSIMILARS MARKET IN 2016 69
FIGURE 18 ONCOLOGY TO DOMINATE THE BIOSIMILARS MARKET IN 2016 73
FIGURE 19 GLOBAL CANCER INCIDENCE, BY REGION, 2012–2020 75
FIGURE 20 EUROPE TO DOMINATE THE BIOSIMILARS MARKET IN 2016 82
FIGURE 21 NORTH AMERICA: BIOSIMILARS MARKET SNAPSHOT 84
FIGURE 22 GLUCAGON SEGMENT TO HOLD THE LARGEST SHARE OF THE NORTH AMERICAN MARKET 86
FIGURE 23 EUROPE: BIOSIMILARS MARKET SNAPSHOT 91
FIGURE 24 ERYTHROPOIETIN SEGMENT TO HOLD THE LARGEST SHARE OF THE EUROPEAN MARKET 93
FIGURE 25 ASIA: BIOSIMILARS MARKET SNAPSHOT 100
FIGURE 26 RECOMBINANT NON-GLYCOSYLATED PROTEINS SEGMENT TO HOLD LARGEST SHARE OF THE ASIAN MARKET 101
FIGURE 27 ONCOLOGY SEGMENT TO HOLD LARGEST SHARE IN THE ASIAN MARKET IN 2016 103
FIGURE 28 ROW: BIOSIMILARS MARKET SNAPSHOT 110
FIGURE 29 GRANULOCYTE COLONY-STIMULATING FACTOR SEGMENT TO HOLD LARGEST SHARE OF THE ROW MARKET IN 2016 111
FIGURE 30 KEY DEVELOPMENTS ADOPTED BY MARKET PLAYERS BETWEEN 2013 AND 2016 113
FIGURE 31 GLOBAL BIOSIMILARS MARKET SHARE, BY KEY PLAYER, 2015 114
FIGURE 32 BATTLE FOR MARKET SHARE: REGULATORY APPROVALS WAS THE KEY STRATEGY PURSUED BY MARKET PLAYERS BETWEEN 2013 & 2016 115
FIGURE 33 PRODUCT BENCHMARKING FOR THE TOP 3 PLAYERS 120
FIGURE 34 COMPANY SNAPSHOT: PFIZER INC. 121
FIGURE 35 COMPANY SNAPSHOT: SANDOZ INTERNATIONAL GMBH 123
FIGURE 36 COMPANY SNAPSHOT: TEVA PHARMACEUTICAL INDUSTRIES LTD. 126
FIGURE 37 COMPANY SNAPSHOT: F. HOFFMANN-LA ROCHE LTD. 128
FIGURE 38 COMPANY SNAPSHOT: AMGEN INC. 130
FIGURE 39 COMPANY SNAPSHOT: BIOCON LTD. 132
FIGURE 40 COMPANY SNAPSHOT: DR. REDDY'S LABORATORIES 134
FIGURE 41 COMPANY SNAPSHOT: CELLTRION INC. 136
FIGURE 42 COMPANY SNAPSHOT: MYLAN INC. 138

If the above report does not have the information suitable for your business, we can provide custom research that can be lucrative for your business or enhance your profession.